Latest Conference Articles

Andrew Bzowyckyi, PharmD, BCPS, CDCES, associate professor at Pacific University Oregon and clinic pharmacist at Legacy Medical Group discusses the differences in GLP-1 receptor agonists and insulin for the management of diabetes.

Melissa Somma McGivney, PharmD, FCCP, FAPhA, professor and associate dean for community partnerships at the University of Pittsburgh School of Pharmacy, gives a brief overview of the best practices when it comes to billing in a pharmacy.

A presentation at the American Pharmacists Association Annual Meeting 2022, highlighted potential innovations for community pharmacies.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the role of the pharmacist in gynecologic oncology patient care and treatment.

Pharmacy Times spoke to Seth DePasquale, RPh, BCSCP, senior director of hospital and health systems at Visante, about his session at the APhA 2022 Annual Meeting & Exposition, titled "Keeping Up with USP 800."

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.

Dr. Seiko Diane Yamada, MD, the 53rd president of Society of Gynecologic Oncology (SGO), discussed her goals for SGO during her tenure.

Pharmacy Times will be covering the upcoming Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer live in Phoenix, Arizona, taking place March 18 through 21.

Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

Although marketing may seem intimidating, pharmacy owners should jump in and discover what works best for their pharmacy.

Tyler Woods, PharmD, pharmacy district manager with VMC Buying Group, discussed how partnering together can help independent pharmacies obtain drugs at a lower cost.

Jen Diehl, CPA, discussed some common financial concerns for independent pharmacies and where she sees the landscape heading in the future.

Pharmacy technicians are continuing to prove their worth as pharmacies shift their focus to the future, according to Jessica Langley-Loep, executive director of education and advocacy at the National Healthcareer Association.

Tom Wheelwright, CPA, founder and CEO of WealthAbility, discussed his perspective on taxes and how pharmacies can use them to their advantage.

Pharmacy Development Services business coach Patrick Lott discussed the impacts that a positive culture and effective leadership can have both on employee satisfaction and patient outcomes.

PDS founder and executive chairman Dan Benamoz, RPh, discussed a few of the most exciting speakers and opportunities happening during the conference.

Marci Strauss, PharmD, discussed how pharmacists are reacting to the ongoing shift toward performance-based reimbursement models.

Dan Benamoz, RPh, founder and executive chairman of PDS, and Chip Phillips, CEO, discussed their plans for the meeting and what they're focused on for the future of pharmacy.

The results of a pilot program investigating the efficacy of remote patient monitoring for patients with cancer showed that it helped to keep high-risk individuals out of the hospital.

Communication, flexibility, and virtual solutions will remain key as the COVID-19 pandemic continues.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.

Judy Neville, program director of the college of pharmacy and pharmacy technician program at the University of Nebraska Medical Cancer, discusses what to look forward to for the AAPT conference in 2022.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, addresses the primary endpoint in the trial assessing zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Patients with hormone receptor-positive breast cancer doubled their median progression-free survival following a switch to fulvestrant plus palbociclib.